Publications by authors named "Maria Victoria Martinez-Sanchez"
Bladder cancer (BC) represents a wide spectrum of diseases, ranging from recurrent non-invasive tumors to advanced stages that require intensive treatments. BC accounts for an estimated 500,000 new cases and 200,000 deaths worldwide every year. Understanding the biology of BC has changed how this disease is diagnosed and treated.
View Article and Find Full Text PDFArticle Synopsis
- Acute lymphoblastic leukemia (ALL) is the most common cancer seen in kids, and measuring residual disease (MRD) helps doctors change treatment to stop it from coming back.
- Researchers looked at 80 kids with ALL and tested their bone marrow samples using three different MRD methods to help decide the best treatment.
- The study found that while MRD testing could help prevent relapses in some patients, better tests are needed to make treatments even more effective, and more research is needed to see if early treatment really helps kids live longer.
Purpose: Although outcomes of children with acute myeloid leukemia (AML) have improved over the last decades, around one-third of patients relapse. Measurable (or minimal) residual disease (MRD) monitoring may guide therapy adjustments or pre-emptive treatments before overt hematological relapse.
Methods: In this study, we review 297 bone marrow samples from 20 real-life pediatric AML patients using three MRD monitoring methods: multiparametric flow cytometry (MFC), fluorescent in situ hybridization (FISH) and polymerase chain reaction (PCR).
Acute leukemia is the most common malignancy in children. Most patients are cured, but refractory/relapsed AML and ALL are the first cause of death from malignancy in children. Maintenance chemotherapy in ALL has improved survival by inducing leukemic cell apoptosis, but immune surveillance effectors such as NK cells might also contribute.
View Article and Find Full Text PDF